International Journal of Gynecological Cancer最新文献

{"title":"Novel scoring system incorporating lipoproteins to predict outcomes of epithelial ovarian cancer patients.","authors":"Song Tang, Fang Zheng, Kelie Chen, Yizhen Niu, Zhiqin Fu, Yihua Wu, Dajing Xia, Weiguo Lu","doi":"10.1136/ijgc-2024-005768","DOIUrl":"10.1136/ijgc-2024-005768","url":null,"abstract":"<p><strong>Objective: </strong>Epithelial ovarian cancer is the most lethal gynecological malignancy worldwide. While common prognostic factors are identified, the impact of serum lipoproteins remains controversial. This retrospective cohort study aims to investigate the association between specific lipoprotein levels and prognosis.</p><p><strong>Methods: </strong>Clinical data of 420 participants with epithelial ovarian cancer registered at Women's Hospital, School of Medicine, Zhejiang University, between January 2014 and April 2021 were included. Cox regression analyses and Kaplan-Meier methods were used to assess prognosis, estimated by hazard ratio (HR) with 95% confidence interval (CI). A novel prognostic model incorporating lipoproteins was developed for evaluating the prognosis. Meta-analysis was applied to assess the impact of low density lipoprotein cholesterol (LDL-C) on prognosis.</p><p><strong>Results: </strong>Among 420 patients, those in advanced stages exhibited higher low density lipoprotein cholesterol (LDL-C) (p=0.008) and lower high density lipoprotein cholesterol (HDL-C) levels (p<0.001), with no significant differences in total cholesterol or triglyceride levels. Elevated LDL-C level was significantly associated with worse overall survival (HR 1.72; 95% CI 1.15 to 2.58; p=0.010) and progression free survival (HR 1.94; 95% CI 1.46 to 2.58; p<0.001), whereas higher HDL-C level was linked to better overall survival (HR 0.56; 95% CI 0.37 to 0.85; p=0.004) and progression free survival (HR 0.61; 95% CI 0.46 to 0.81; p<0.001). A novel prognostic model, low density lipoprotein cholesterol-high density lipoprotein cholesterol-fibrinogen-lactate dehydrogenase-prealbumin-Fe-stage (LH-FLPFS), was established to enhance prognostic predictive efficacy. The meta-analysis further suggested that higher LDL-C level was associated with worse overall survival (HR 1.82; 95% CI 1.39 to 2.38; p<0.001).</p><p><strong>Conclusions: </strong>In this study, preoperative LDL-C and HDL-C levels emerged as potential prognostic factors for ovarian cancer. Establishment of a novel prognostic model, LH-FLPFS, holds promise for significantly improving prognostic predictive efficacy.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101855"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The intriguing overall survival results of the PRIMA trial.","authors":"Mariana Carvalho Gouveia, Letícia Vecchi Leis, Letícia de Mello Graziano, Mariana Scaranti","doi":"10.1136/ijgc-2024-006187","DOIUrl":"10.1136/ijgc-2024-006187","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101837"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The histopathologic and molecular findings of neurotrophic tyrosine kinase receptor-rearranged uterine sarcoma.","authors":"Whitney Rich, Natalie Banet","doi":"10.1016/j.ijgc.2025.101898","DOIUrl":"10.1016/j.ijgc.2025.101898","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101898"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When Impact Multiplies: Defining Trials and Insights from the 2025 Society of Gynecologic Oncology Annual Meeting.","authors":"Mariana Carvalho Gouveia, Jéssica Monteiro Vasconcellos, Letícia Vecchi Leis, Mariana Scaranti","doi":"10.1016/j.ijgc.2025.101895","DOIUrl":"10.1016/j.ijgc.2025.101895","url":null,"abstract":"<p><p>\"When Impact Multiplies: Defining Trials and Insights From the 2025 Society of Gynecologic Oncology Annual Meeting\" features the most significant and potentially practice-changing research presented at the Annual Meeting on Women's Cancer. Held in Seattle, WA from March 14 to 17, 2025, the Society of Gynecologic Oncology Annual Meeting remains one of the premier conferences for professionals dedicated to advancing gynecologic cancer care. The scientific program covered a broad spectrum of topics across gynecologic oncology, highlighting the latest advancements in research, clinical practice, and patient-centered care. From this comprehensive program, we selected 14 studies considered to be highly impactful.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101895"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A complete hydatidiform mole coexisting with a fetus.","authors":"Yating Zhao, Jianhua Qian","doi":"10.1136/ijgc-2024-005591","DOIUrl":"10.1136/ijgc-2024-005591","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101888"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to 'Controversies in vulvar cancer: revisiting the margin of error' [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101678].","authors":"Maureen E Byrne, Mario M Leitao, Nadeem R Abu-Rustum","doi":"10.1016/j.ijgc.2025.101955","DOIUrl":"10.1016/j.ijgc.2025.101955","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101955"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer.","authors":"Alejandro Perez-Fidalgo, Barbara Schmalfeldt, Angela George, Charlie Gourley, Sandro Pignata, Domenica Lorusso, Maria Pilar Barretina-Ginesta, Ignacio Romero, Christoph Grimm, Toon Van Gorp, Maria Rossing, Dearbhaile C Collins, Josefin Fernebro, Line Bjørge, Alexandra Leary, Thibault de la Motte Rouge, Philipp Harter, Christian Kurzeder, Joana Savva-Bordalo, Benoit You","doi":"10.1136/ijgc-2024-005497","DOIUrl":"10.1136/ijgc-2024-005497","url":null,"abstract":"<p><strong>Objectives: </strong>Maintenance therapies, including poly (ADP-ribose) polymerase (PARP) inhibitors and/or bevacizumab, have substantially improved the prognosis of patients with advanced ovarian cancer. Owing to the variability in treatment strategies across Europe, a Delphi study was conducted among European experts to understand the heterogeneity of clinical practice and identify key factors driving maintenance treatment decisions for advanced ovarian cancer.</p><p><strong>Methods: </strong>A pragmatic literature review was conducted to identify key questions regarding maintenance treatment strategies in patients with advanced ovarian cancer. Utilizing a Delphi methodology, consensus was assessed among a panel of 16 experts using a questionnaire based on results of the pragmatic literature review.</p><p><strong>Results: </strong>Panelists agreed that BRCA mutation and homologous recombination status should be assessed in parallel at diagnosis, and that first-line platinum chemotherapy may be initiated concurrently. There was a consensus that alternative homologous recombination deficiency tests are acceptable provided they are clinically validated. Panelists agreed that Response Evaluation Criteria in Solid Tumors (RECIST) and CA-125 elimination rate constant K (KELIM) scores can help assess tumor chemosensitivity and guide treatment-related decisions. Panelists defined high-risk disease as International Federation of Gynecology and Obstetrics (FIGO) stage IV disease or stage III with residual disease after initial/ interval cytoreduction. Risk of disease progression was a key determinant of choice between PARP inhibitor, bevacizumab, or both in combination, as maintenance therapy in advanced ovarian cancer.</p><p><strong>Conclusions: </strong>Key drivers for selecting advanced ovarian cancer maintenance treatments include tumor mutational status as a key biomarker and clinician perception of the risk for early disease progression.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101863"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival outcomes and safety of nimotuzumab combined with radiotherapy ± chemotherapy for locally advanced cervical cancer.","authors":"Jiwei Li, Manbo Cai, Changjun Xie, Sijuan Ding, Tao Wu, Wen Zou, Jingjing Wang","doi":"10.1016/j.ijgc.2025.101930","DOIUrl":"10.1016/j.ijgc.2025.101930","url":null,"abstract":"<p><strong>Objective: </strong>Chemoradiotherapy is currently the main treatment for locally advanced cervical cancer. Nevertheless, the survival profile of locally advanced cervical cancer patients remains unsatisfactory because of metastasis and recurrence. We aimed to assess the survival outcomes and safety of radiotherapy ± chemotherapy combined with nimotuzumab (a human monoclonal antibody against epidermal growth factor receptor that has anti-tumor activities) for patients with locally advanced cervical cancer.</p><p><strong>Methods: </strong>Patients with stage IIB to IVA (International Federation of Gynecology and Obstetrics 2018) pathological and diagnosed locally advanced cervical cancer from January 2021 to December 2022 were collected in this retrospective, multi-center, and single-arm study. All patients received platinum-based radiotherapy ± chemotherapy with nimotuzumab (200 mg once a week for 6 weeks). Primary end point was overall survival. Secondary end points were progression-free survival and safety. The adverse events were recorded. Statistical analysis was performed using Statistics Analysis System software (v 9.4).</p><p><strong>Results: </strong>A total of 60 patients were collected with a median follow-up of 17.4 months (95% CI 14.8 to 19.2). The median age was 58 years (range; 35-90). A total of 16 patients (26.7%) had stage II, 38 patients (63.3%) had stage Ⅲ, and 6 patients (10%) had stage Ⅳ. The median overall survival was not reached, and the median progression-free survival was 20.4 months (95% CI 16.3 to not evaluable). Radiotherapy ± chemotherapy with nimotuzumab achieved 90.7% 1- and 2-year overall survival. Moreover, 1-year progression-free survival was 82.1%, and the 2-year progression-free survival was 47.7%. The most common treatment-related grade 3 to 4 adverse events included neutropenia (15%), anemia (21.7%), and thrombocytopenia (5%). No drug-related severe adverse events or deaths occurred.</p><p><strong>Conclusions: </strong>The addition of nimotuzumab to radiotherapy ± chemotherapy was associated with favorable oncologic outcomes for patients with locally advanced cervical cancer, and the toxicity was tolerable and manageable.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101930"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Key highlights from American Society of Clinical Oncology 2025: top 10 studies in gynecologic oncology.","authors":"Jéssica Monteiro Vasconcellos, Letícia Vecchi Leis, Mariana Carvalho Gouveia, Mariana Scaranti","doi":"10.1016/j.ijgc.2025.101994","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101994","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 9","pages":"101994"},"PeriodicalIF":4.1,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The GOG Foundation and EVA/LACOG partnership: a collaborative strategic alliance for clinical trial execution.","authors":"Fernando Maluf, Robert L Coleman, Angélica Nogueira-Rodrigues, Bradley J Monk, Glauco Baiocchi, Kathleen N Moore, Andréia Cristina de Melo, David M O'Malley, Graziela Z Dal Molin, Leslie M Randall, Gonzalo Giornelli, Brian Slomovitz, René Pareja, Bhavana Pothuri, Ramez N Eskander, Gustavo Werutsky, Thomas J Herzog","doi":"10.1016/j.ijgc.2025.101991","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101991","url":null,"abstract":"<p><p>The collaborative efforts between GOG and LACOG are aimed at advancing clinical oncology research through strategic global partnerships, particularly related to the conduct of clinical trials. Herein, we provide the framework of this relationship addressing key operational components including establishing a shared Publication Policy. In addition, this initiative seeks to standardize contributions, recognize authorship fairly, and ensure compliance with agreed protocols. Emphasis is placed on critical practices like study design, data interpretation, manuscript development, and intellectual review. The Policy considers the roles of individual scientists, institutional sponsors, and contributors while ensuring transparency and authenticity in scientific communication. This collaborative approach underscores the importance of collective expertise in addressing global challenges in oncology and fostering innovation through multi-institutional cooperation. The manuscript outlines the processes for critical review, approval, and publication, ensuring credibility in the dissemination of scientific findings to the community. These frameworks aim to promote inclusivity, equitable representation, and the advancement of oncology knowledge.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101991"},"PeriodicalIF":4.1,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}